share_log
Moomoo 24/7 ·  03/28 11:45

Immuneering Shares Are Trading Higher. The Company Yesterday Announced That the First Patient Has Been Dosed in Its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations

Immuneering股票交易價格走高。該公司昨天宣佈,在 IMM-6-415 的 1/2a 期試驗中,第一位患者已服藥,用於治療帶有 RAF 或 RAS 突變的晚期實體瘤

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論